We report a case of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis induced by propylthiouracil (PTU), and review the literature concerning to anti-thyroid drug-induced ANCA-associated vasculitis.
SMALL vessel vasculitis is associated with immunecomplex, anti-neutrophil cytoplasmic antibody (AN-CA) or paraneoplasma [1] . Concerning small vessel vasculitis in patients with Graves' disease including that induced by anti-thyroid drugs, immune-complex vasculitis [2] and cutaneous vasculitis [3] have been reported. Recently, ANCA-associated vasculitis has also been described based on pathological findings and the clinical course [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . However, there has not been any detailed discussion concerning drug dose and duration of anti-thyroid drug use, or titers of myeloperoxidase (MPO)-ANCA, anti-nuclear antibody (ANA) and anti-thyroid antibodies. It is interesting that most cases were reported from Japan Japanese Red Cross-Nagasaki Atomic Bomb Hospital, 3-15, Morimachi, Nagasaki 852-8511, Japan [4] [5] [6] [7] [8] [9] [10] [11] , but it is not clear why anti-thyroid drug-induced Q~NCA-associated vasculitis mainly happens to Japanese.
Here we report a case of ANCA-associated vasculitis induced by propylthiouracil (PTU), and review the literature on anti-thyroid drug-induced ANCAassociated vasculitis, especially concerning the above.
Case presentation
A 45-year-old man with palpitation, hand tremor and weight loss consulted our hospital in January 1998. He had diffuse goiter and positive microsome test (6400 x ; Serodia-AMC, Fujirebio Inc., Japan), but negative thyroid test (Serodia-ATG, Fujirebio Inc.). Serum concentrations of free thyroxine, free triiodothyronine and thyroid stimulating hormone (TSH) were 3.8 ng/dl (Amerlex-MAB FT4, Amersham, UK), 11.0 pg/ml (Amerlex-MAB FT3, Amer-sham) and less than 0.1pIU/ml (Axsym TSH Dainapack, Abbott Laboratories, USA), respectively. Serum TSH receptor-antibody was positive (40.0%). On 99 mTc-thyroid scintigram, diffuse and high uptake in the thyroid gland was noted. Therefore, he was diagnosed with Graves' disease. We did not measure MPO-ANCA or ANA before treatment with anti-thyroid drug. As he had itching caused by thiamazole, PTU was started in March 1998. While he was in the euthyroid state using 150 mg (3 tablets)/day of PTU in February 1999, general arthralgia, especially in both shoulders and knees, and low grade fever appeared. There was no respiratory, intestinal or urinary infection suggesting reactive arthritis. There was no specific symptom or sign of rheumatic diseases, and LE cell, immune complex, rheumatoid factor, anti-dsDNA or anti-ssDNA antibodies (Mesacup DNA-II ds or ss test, Medical and Biological Laboratories (MBL), Japan) were negative, although ANA (Fluoro HEPANA test, MBL) was positive (20 x , diffuse type). Degree and distribution of arthralgia and degree of fever gradually progressed over more than 2 months without pulmonary, skin or eye involvement. Laboratory findings of urine and blood were normal, except for positive MPO-ANCA (191EU; NephroScholar MPO-ANC, Nissho Co., Japan) and PR3-ANCA findings (37EU; NephroScholar C-ANC, Euro-Diagnostica AB Co., Sweden). After PTU was discontinued without steroid or immune modulation drugs, both symptoms disappeared, following which serum lgvels of PR3-ANCA normalized rapidly, and those of MPO-ANCA decreased.
Discussion
Characteristic findings of anti-thyroid drug-induced ANCA-associated vasculitis are that 1) most patients were resistant to drug (mainly PTU) treatment of Graves' disease [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . They had received high doses of PTU (mean =about 5 tablets/day) usually over a prolonged period (mean = about 4 years) from the start of anti-thyroid drug until the onset of ANCA-associated vasculitis.
2) Most patients had high titers of MPO-ANCA (mean = about 250 EU/ml, two thirds of patients had more than 100 EU/ml).
Moreover, clinical symptoms disappeared according to decreasing values of MPO-ANCA.
Although there have been several reported ANCA-positive patients treated with antithyroid drug without clinical manifestations of vasculitis, their titers of MPO-ANCA were lower than those in most patients with vasculitis. Therefore, a high threshold titer of MPO-ANCA may be necessary to induce vasculitis, especially pulmonary renal syndrome, in most cases. 3) Positivity for antithyroid peroxidase (TPO) and anti-thyroglobulin antibodies was similar to that in untreated Graves' patients.
However, the incidence (about half of patients) and titers (20-2560 fold) of ANA were higher than those of untreated patients with Graves' disease [23] . Moreover, ANA disappeared in some cases after the cessation of drug and treatment of vasculitis [5, 18] . 4) Comparison between Japanese cases and others showed a similar gender distribution, age at onset, anti-thyroid drug used, mean duration, drug dose, and pathological findings, treatment and prognosis of ANCA-associated vasculitis. The reason why anti-thyroid drug-induced ANCAassociated vasculitis mainly occurs in Japanese remains unclear. However, it may be that most patients with resistance to drug treatment in Japan hesitate to receive radioisotope therapy or thyroidectomy and have taken high doses of drugs over longer periods compared to those of patients in other countries. 5) Although prognosis was better than that of idiopathic ANCA-associated vasculitis, many patients had renal and/or pulmonary symptoms and received therapy with steroids and/or immunosuppressive drugs.
Arthralgia and fever are the most common involvements of anti-thyroid drug-induced ANCA-associated vasculitis. Our case had these symptoms for a long period without specific symptom, sign or laboratory data of other arthritis. Dolman et al. [14] reported mild cases of PTU-induced ANCA-associated vasculitis like ours. Many reports revealed that pathological findings of vasculitis were related to ANCA, and MPO-ANCA is thought to be a specific marker of anti-thyroid drug-induced ANCA-associated vasculitis. Our patient also had high titer of MPO-ANCA and PR3-ANCA, and titers of ANCA decreased in correlation with the course of symptoms after the cessation of PTU. Although we did not obtain pathological findings as the patient did not have renal, pulmonary or skin involvement for biopsy, we diagnosed that he was PTU-induced AN-
CA-associated vasculitis. Most cases of pulmonary renal syndrome had anti-thyroid drugs over a long period (usually several years). Some cases only demonstrated fever and/or arthralgia for a prolonged period before onset of pulmonary renal syndrome. The interval in our case was shorter than those in most patients. It is suggested that our case was diagnosed at an early stage of ANCA-associated vasculitis before the onset of pulmonary or renal involvement.
Although it was reported that aspecific (atypical) ANCAs were detected by immunofluorescence in some patients with Graves' disease [24, 25] , MPO-ANCA assessed by ELISA may not appear in untreated patients with Graves' disease [14, 24, 25] . There may be a specific reason why the anti-thyroid drug itself, especially PTU, can induce MPO-ANCA and ANCA-associated vasculitis. It was previously reported that PTU accumulates in neutrophils and binds to MPO [26, 27] . Lee et al. [27] reported that repeated administration of PTU altered the MPO structure surrounding the heme iron. It is suggested that changing the configuration of MPO may induce the antigenicity.
In summary, we reported a case of ANCA-associated vasculitis induced by PTU, and reviewed the literature. Anti-thyroid drug-induced ANCAassociated vasculitis usually happens to Graves' patients with resistance to drug treatment (mainly PTU, receiving high doses over a prolonged period) and with high titers of MPO-ANCA and ANA.
